Mr. Speaker, I yield such time as she may consume to the gentlewoman from North Carolina (Ms. Adams).

Mr. Speaker, I yield myself such time as I may consume. Mr. Speaker, I would like to thank Chairman Kline, Subcommittee Chair Rokita, and the gentleman from Florida (Mr. Curbelo) for their work, and also, on our side, Representatives Davis…

I did read your testimony, Ms. Bresch, and I was not impressed.

I am expecting Congress now to take a much different leadership role.

I propose that maybe we need a price protection program for public health drugs, and that we need to decide a public formulary.

You have 94 percent of the market share.

I would like to just begin by trying to create a sense of context and proportion.

I don't care what your profit is. I mean, America is built on profits. Profits are an incentive.

So what happened between 2007 and 2016 different than the previous manufacturer and producer?

I'm tired of paying prescription drug companies and drug manufacturers and device companies to treak these issues.

Mr. Speaker, I thank the gentlewoman from the District of Columbia (Ms. Norton) and the gentleman from Georgia (Mr. Carter), my good friends, for their leadership in managing today. I rise today, Mr. Speaker, in strong support of this…

Mylan has received more than $4 billion in net sales revenue on this one drug over the last decade.

I was just struck with what humanitarians you people of Mylan really are.

I think I know what good and bad management looks like.

I have that courage. I believe my colleagues do too.

There's one message for us here in the public and quite another for investors.

You should foresee that just continuing as we continue to maximize the EpiPen franchise.

You virtually have a monopoly and you've used it to your advantage, but, unfortunately, it's at the expense of people who need it.